Latest studies
- RecruitingPHASE2, PHASE3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
This study is looking at a new medicine, RO7771950, for HER2-positive breast cancer that has spread or is hard to remove. It compares RO7771950 with an existing medicine, tucatinib, both given with trastuzumab and capecitabine. The aim is to see if the new medicine works well and is safe.
HER2-positive Breast CancerThailand - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
This study looks at a new drug, claseprubart, for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It aims to see if the drug helps people with CIDP and if it's safe. Some participants will receive the drug, and others a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyThailand - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
DLBCLDiffuse Large B-Cell LymphomaThailand - RecruitingPHASE3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
This study looks at the long-term safety of a new medicine, ianalumab, for people with lupus. It's for those who have already been in an earlier ianalumab study and continues to check how safe and well the medicine is tolerated over time.
Systemic Lupus ErythematosusThailand - Active not recruitingPHASE3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
This study compares a new drug, SB27, with an existing one, Keytruda, for advanced lung cancer. Both are given with chemotherapy. Researchers want to see if SB27 works as well as Keytruda for patients with non-small cell lung cancer that has spread.
Non-small Cell Lung Cancer Stage IVThailand - Recruiting
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
This study looks at how well Boston Scientific's special drug-coated devices work in treating blood vessel problems in people's arms and legs. It helps doctors understand their real-world use for conditions like Peripheral Vascular Disease.
Peripheral Vascular DiseasesThailand - Recruiting
Quality of Pediatric Resuscitation in a Multicenter Collaborative
This study looks at how the quality of CPR given to children during a cardiac arrest affects their recovery. Researchers are observing children in hospitals to see if better CPR techniques and after-care improve survival and brain function.
Cardiac ArrestCardiopulmonary ArrestThailand - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
Hepatocellular CarcinomaThailand - Active not recruitingPHASE3
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
This study is testing new treatments for liver cancer (hepatocellular carcinoma) in people who have had their cancer removed but are at high risk of it coming back. It compares a drug called durvalumab, alone or with bevacizumab, against a dummy treatment (placebo) to see if they can prevent the cancer from returning.
Hepatocellular CarcinomaThailand - RecruitingPHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
This study looks at a new drug, zilovertamab vedotin, combined with standard treatment for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). Researchers want to see if this new combination helps people live longer without their cancer growing or spreading, compared to standard treatment alone.
Diffuse Large B-Cell LymphomaThailand - RecruitingPHASE3
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
This study is looking at a new medicine called Elecoglipron for people with certain types of heart failure. It compares Elecoglipron to a dummy medicine (placebo) to see if it helps improve heart health outcomes for adults already taking other heart failure medications, including dapagliflozin.
Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)Thailand - RecruitingPHASE3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
This study looks at a new medicine called elecoglipron for people with long-term kidney disease. We want to see if it helps improve health compared to a dummy pill (placebo). Participants will also be taking existing kidney disease treatments like dapagliflozin. It's a large study, involving many people to get clear results.
Chronic Kidney DiseaseThailand - RecruitingPHASE3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
This study is testing a new medicine, Molnupiravir, to see if it can stop people at high risk of severe COVID-19 from becoming very ill. It's for people who can't take other COVID-19 treatments. We want to find out if it works better than a dummy treatment.
Coronavirus Disease (COVID-19)Thailand - RecruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal CancerThailand - RecruitingPHASE2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
This study is looking into a new medicine called Ianalumab for people in the UK with a specific type of scleroderma called diffuse cutaneous systemic sclerosis. It aims to see if the drug is safe and helps with symptoms, compared to a dummy treatment.
Diffuse Cutaneous Systemic SclerosisThailand - Active not recruitingPHASE4
CINC424A2X01B Rollover Protocol
This study is for patients already taking ruxolitinib, or ruxolitinib with panobinostat, in a previous trial, and who are still benefiting. It lets them continue their treatment and helps researchers learn more about the long-term safety of these medications.
Primary MyelofibrosisPolycythemia VeraGraft Versus Host DiseaseAcute Myeloid LeukemiaThailand - Active not recruitingPHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This study allows some cancer patients who are already benefiting from certain treatments in another study to continue receiving that treatment. It’s for those who wouldn't be able to get the treatment otherwise, helping them keep accessing therapies that are working for them.
CancerThailand - Not yet recruitingPHASE3
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
This study is for people who were in a previous trial for a medicine called anifrolumab (Saphnelo) and found it helpful. It lets you keep taking the medicine to see if it continues to work and monitor your safety.
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus ErythematosusThailand - Active not recruitingPHASE3
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
This study looks at a new medicine called remibrutinib for chronic spontaneous urticaria (CSU), comparing it to a dummy treatment (placebo) and another existing medicine, omalizumab. It aims to see if remibrutinib is safe and helps reduce hives and itching in adults whose CSU isn't well controlled by usual allergy medicines.
Chronic Spontaneous UrticariaThailand - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
This study looks at a new drug, sacituzumab tirumotecan, for people with a type of lung cancer (non-small cell lung cancer) that has specific genetic changes and has worsened after previous treatments. It compares this new drug to a standard chemotherapy combination to see if it improves survival.
Non-small Cell Lung Cancer (NSCLC)Thailand - Active not recruitingPHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
This study is testing new combinations of medicines for advanced kidney cancer (renal cell carcinoma). Its aim is to see if these new combinations work better and are safe compared to a standard treatment, for people who haven't had treatment for their advanced cancer before.
Carcinoma, Renal CellThailand - Active not recruitingPHASE3
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
This study looks at a new weekly medicine, somapacitan, for children who need help growing. It compares it to Norditropin®, a daily medicine already used. The study includes children born small, or with Turner, Noonan syndrome, or unexplained short stature, over up to 5.5 years.
SGA, Turner Syndrome, Noonan Syndrome, ISSThailand - Active not recruitingPHASE2
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
This study looks at a new combination of two medicines, baxdrostat and dapagliflozin, for people with lasting kidney disease and high blood pressure. We want to see if this combination can lower a protein called albumin in the urine, which is a sign of kidney damage.
Chronic Kidney Disease and HypertensionThailand - Active not recruitingPHASE3
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
This study is testing a new HPV vaccine in men aged 20-45. We want to see if it can prevent certain HPV infections in the mouth and if it’s safe. It's compared to a dummy injection to see if it works.
Papillomavirus InfectionsThailand - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
This study is for women with cervical cancer that has spread. It's testing new combinations of medicines (sac-TMT, pembrolizumab, and possibly bevacizumab) to see if they are safe and can help people live longer or stop their cancer from getting worse.
Cervical CancerThailand - Active not recruitingPHASE3
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
This study is testing if a medicine called selexipag can help children aged 2-17 with a serious lung condition called pulmonary hypertension. It aims to see if adding selexipag to their usual treatment can slow down the disease compared to a dummy medicine.
Hypertension, PulmonaryThailand - RecruitingPHASE2
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
This study looks at a new medicine called luspatercept for people with a type of anaemia called alpha-thalassaemia. It aims to see if the medicine is safe and helps reduce the need for blood transfusions.
AnemiaThailand - Active not recruitingPHASE3
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This study compares a new drug, alectinib, with standard chemotherapy for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after surgery. We want to see if alectinib is better at stopping the cancer from coming back and if it's safe.
Carcinoma, Non-Small-Cell LungThailand - Active not recruitingPHASE3
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is looking at how well two new drugs, enfortumab vedotin and pembrolizumab, work together to treat advanced bladder cancer that has spread. It compares them to standard chemotherapy treatments to see if they are a better option.
Urothelial CancerThailand - Active not recruitingPHASE3
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
This study looks at a new combination of treatments for a type of advanced lung cancer. It compares a drug called amivantamab plus standard chemotherapy to chemotherapy alone, to see if the combination works better at stopping the cancer from growing.
Carcinoma, Non-Small-Cell LungThailand - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at two new drug combinations, amivantamab and lazertinib, compared to a standard drug, osimertinib, for people in the UK with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation).
Carcinoma, Non-Small-Cell LungThailand - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseThailand - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This study compares a new drug, Giredestrant, with standard hormone therapy for early breast cancer. It's for people with a specific type of breast cancer (ER-positive, HER2-negative) who have already had surgery.
Early Breast CancerThailand - Active not recruitingPHASE3
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
This study is testing a new injection, anifrolumab, for adults aged 18-70 with moderate to severe lupus (SLE) in the UK. Researchers want to see if it's safe and helps improve symptoms when added to their usual lupus treatment. Half get the new drug, half get a dummy drug.
Systemic Lupus ErythematosusThailand - RecruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisThailand - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsThailand - Active not recruitingPHASE3
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
This study is testing a new drug called odronextamab with chemotherapy for follicular lymphoma. It compares this new combination to the usual treatment (rituximab with chemotherapy) to see if it's safe, works well, and helps people with this type of cancer.
Follicular Lymphoma (FL)Thailand - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Thailand - Active not recruitingPHASE1
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
This study is for adults with head and neck cancer that has spread or returned. It tests if combining new medicines like BI 770371, pembrolizumab, and cetuximab can shrink tumors better than pembrolizumab alone. It aims to see if these combinations help the immune system fight cancer.
Head and Neck Squamous Cell CarcinomaThailand - Active not recruitingPHASE3
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This study is looking at a new medicine called Dato-DXd for advanced triple-negative breast cancer. It compares Dato-DXd with standard chemotherapy in patients who cannot have a specific type of immunotherapy. The aim is to see if Dato-DXd is better at shrinking tumours and helping people live longer.
Breast CancerThailand - RecruitingPHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This study looks at a new treatment called Pumitamig for advanced non-small cell lung cancer that hasn't been treated before. It compares Pumitamig to an existing treatment, Pembrolizumab, in people whose cancer cells have a high level of a specific marker called PD-L1.
Non-Small Cell Lung Cancer (NSCLC)Thailand - Active not recruitingPHASE3
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
This study is looking into a new drug, zipalertinib, for people with a certain type of lung cancer (NSCLC) in its early stages. It compares zipalertinib with standard chemotherapy to a dummy pill (placebo) with standard chemotherapy after surgery.
Lung CancerAdjuvantPost-surgicalEGFRThailand - Active not recruitingPHASE3
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
This study is testing a new medicine called sibeprenlimab for a kidney disease called IgA nephropathy (IgAN). It aims to see if the medicine can reduce protein in the urine and protect kidney function over time, compared to a dummy medicine.
Immunoglobulin A NephropathyThailand - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
Non Small Cell Lung Cancer NSCLCThailand - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisThailand - Active not recruitingPHASE3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
This study is looking at a new medicine called milvexian to see if it can help prevent another stroke in people who have recently had a mini-stroke or a type of stroke called an ischemic stroke.
Ischemic Stroke; Ischemic Attack, TransientThailand - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
This study is looking into a new medicine called apraglutide for adults with a condition called Short Bowel Syndrome (SBS) where their intestines don't absorb enough nutrients. It will compare apraglutide to a dummy medicine (placebo) to see how safe and effective it is.
Short Bowel Syndrome (SBS)SBS Associated With Intestinal Failure (SBS-IF)Thailand - Active not recruitingPHASE2
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
This study is checking if the benefits of bepirovirsen for Hepatitis B last over time. It's for people who previously took part in a bepirovirsen trial and showed good results. No new treatment is given in this follow-up study, just monitoring.
Hepatitis BThailand - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
Breast CancerThailand - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
Non-small Cell Lung Cancer (NSCLC)Thailand